ENTA

12.84

1.52% -0.32

Dopo l'orario di chiusura: 12.83 -0.010 -0.08%

Enanta Pharmaceuticals Inc (ENTA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$13.16

Aprire:

$13.13

Volume 24 ore:

276.57K

Relative Volume:

1.34

Capitalizzazione di mercato:

$373.97M

Reddito:

$69.21M

Utile/perdita netta:

$-61.98M

Rapporto P/E:

-4.9485

EPS:

-2.5947

Flusso di cassa netto:

$-9.61M

1 W Prestazione:

-6.15%

1M Prestazione:

-5.68%

6M Prestazione:

-6.49%

1 anno Prestazione:

+62.00%

Intervallo 1D:

$12.59

$13.32

Intervallo di 1 settimana:

$12.59

$13.98

Portata 52W:

$7.05

$17.15

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Nome

Enanta Pharmaceuticals Inc

Settore

Healthcare (1089)

Industria

Biotechnology (604)

Telefono

617 607 0800

Indirizzo

4 KINGSBURY AVENUE, WATERTOWN, MA

Dipendente

120

Cinguettio

@EnantaPharma

Prossima data di guadagno

2026-08-10

Ultimi documenti SEC

ENTA's Discussions on Twitter

Compare ENTA vs VRTX, REGN, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ENTA Enanta Pharmaceuticals Inc	12.84	383.29M	69.21M	-61.98M	-9.61M	-2.5947
VRTX Vertex Pharmaceuticals Inc	515.57	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.86	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	986.80	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.94	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.66	39.31B	5.76B	514.49M	1.10B	4.4813

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-26	Iniziato	Rodman & Renshaw	Buy
2025-11-14	Iniziato	JP Morgan	Overweight
2025-10-01	Aggiornamento	Jefferies	Hold → Buy
2025-07-28	Ripresa	H.C. Wainwright	Buy
2023-08-09	Downgrade	JP Morgan	Neutral → Underweight
2023-08-08	Downgrade	Jefferies	Buy → Hold
2022-12-09	Iniziato	H.C. Wainwright	Buy
2022-07-06	Aggiornamento	Evercore ISI	In-line → Outperform
2022-06-01	Aggiornamento	Evercore ISI	Underperform → In-line
2021-10-07	Iniziato	Jefferies	Buy
2021-09-09	Iniziato	SVB Leerink	Mkt Perform
2021-01-29	Aggiornamento	JP Morgan	Underweight → Neutral
2020-11-24	Iniziato	Evercore ISI	Underperform
2020-08-28	Ripresa	ROTH Capital	Buy
2020-08-26	Iniziato	Piper Sandler	Overweight
2020-07-27	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2020-03-17	Aggiornamento	Robert W. Baird	Neutral → Outperform
2019-11-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2019-09-26	Downgrade	JP Morgan	Neutral → Underweight
2019-05-24	Iniziato	Wolfe Research	Outperform
2019-04-23	Aggiornamento	Berenberg	Hold → Buy
2018-12-13	Iniziato	Berenberg	Hold
2018-06-06	Iniziato	ROTH Capital	Buy
2018-02-08	Downgrade	JP Morgan	Overweight → Neutral
2018-01-02	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2017-11-21	Reiterato	RBC Capital Mkts	Outperform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2017-07-11	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2016-04-28	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Reiterato	Barclays	Underweight
2015-10-23	Downgrade	Barclays	Equal Weight → Underweight
2015-10-23	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform

Mostra tutto

Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie

Aug 14, 2026

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Share Price, ENTA Stock News, ENTA Share Price & Updates - kalkine.com.au

Aug 14, 2026

Aug 12, 2026

Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses - Sahm

Aug 12, 2026

Aug 11, 2026

H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Aug 11, 2026

Aug 10, 2026

Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline - scanx.trade

Aug 10, 2026

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates - NewsBreak: Local News & Alerts

Aug 10, 2026

Is Enanta Pharmaceuticals (ENTA) Overvalued After Q3 Earnings Mi - GuruFocus

Aug 10, 2026

Enanta Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com - Investing.com Canada

Aug 10, 2026

Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss - TradingKey

Aug 10, 2026

Enanta Pharma misses Q3 estimates on lower royalty revenue - Investing.com

Aug 10, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS - marketbeat.com

Aug 10, 2026

Enanta Pharmaceuticals reports Q3 loss; revenue $14.4M, cash and securities $211.5M - TradingView

Aug 10, 2026

Enanta Pharma On Track to File IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select MRGPRX2 Development Candidate, in 2H >ENTA - Moomoo

Aug 10, 2026

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - AOL.com

Aug 10, 2026

Press Release: Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2026 - Moomoo

Aug 10, 2026

Aug 07, 2026

Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView

Aug 07, 2026

Enanta Pharmaceuticals (ENTA) Climbs 3.2% as Shares Test Key Resistance at $14.46Market Profile - dars.gov.et

Aug 07, 2026

Aug 06, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 06, 2026

(ENTA) Risk Channels and Responsive Allocation - Stock Traders Daily

Aug 06, 2026

Aug 03, 2026

Enanta Pharmaceuticals (ENTA) Expected to Post Quarterly Earnings on Monday - MarketBeat

Aug 03, 2026

Jul 30, 2026